TREM2
Reactivité: Souris
FACS
Hôte: Rat
Monoclonal
78-18
PE
Indications d'application
Optimal dilution of the TREM2 antibody should be determined by the researcher.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
1 mg/mL in 1X PBS, BSA free, sodium azide free
Agent conservateur
Azide free
Stock
-20 °C
Stockage commentaire
Aliquot the TREM2 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
Antigène
TREM2
(Triggering Receptor Expressed On Myeloid Cells 2 (TREM2))
Autre désignation
TREM2
Sujet
Polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), known as Nasu-Hakola disease , is a recessively inherited disease where individuals display early-onset progressive dementia and bone cysts, which leads to death. Mutations in TYROBP (DAP12), which codes for a membrane receptor component in natural-killer and myeloid cells and mutations in triggering receptor expressed on myeloid cells-2 (TREM-2), correlate well to the pathology of PLOSL. TREM-2 is a cell surface receptor on human monocyte-derived dendritic cells that forms a receptor signaling complex with DAP12 and triggers activation of the immune response in macrophages and dendritic cells (DC). The TREM-2/DAP12 complex is a molecular promoter of upregulation of CC chemokine receptor 7, partial DC maturation, and DC survival through activation of protein tyrosine kinases and extracellular signal regulated kinase. The human chronic inflammatory TREM-2 gene maps to chromosome 6p21.1 and encodes a 230 amino acid protein.